XRCC1基因多态性对晚期胃癌患者化疗疗效及生存期的影响
x

请在关注微信后,向客服人员索取文件

篇名: XRCC1基因多态性对晚期胃癌患者化疗疗效及生存期的影响
TITLE:
摘要: 目的:考察X射线损伤修复交叉互补基因1(XRCC1)Arg399Gln(G→A)多态性对晚期胃癌患者奥沙利铂+氟尿嘧啶化疗疗效及生存期的影响。方法:选取2013年1月-2015年1月海南省人民医院晚期胃癌患者52例,予奥沙利铂+氟尿嘧啶联合化疗,每3周为1个周期,均治疗3个周期以上。采用聚合酶链反应-连接酶检测反应法测定患者的基因型,比较不同基因型患者的疾病控制率和无进展生存期。结果:52例晚期胃癌患者中,XRCC1 GG基因型28例(53.8%)、GA基因型21例(40.4%)、AA基因型3例(5.8%),各基因型频率均符合Hardy-Weinberg平衡(P>0.05)。52例患者的疾病控制率为76.9%,其中GG基因型患者的疾病控制率(92.9%)显著高于GA+AA基因型(58.3%),差异有统计学意义(P<0.05);52例患者的平均无进展生存期为(7.1±1.2)个月,其中GG基因型患者的无进展生存期[(8.6±0.8)个月]显著长于GG+GA基因型[(5.9±0.7)个月],差异有统计学意义(P<0.05)。结论:XRCC1多态性与晚期胃癌患者奥沙利铂+氟尿嘧啶化疗疗效及无进展生存期有关,且XRCC1 GG基因型患者对化疗药物更敏感;该基因可能成为该类方案化疗疗效及生存期的预测标志物。
ABSTRACT: OBJECTIVE: To investigate the effect of X-ray repair cross complementing gene (XRCC1) Arg399Gln (G→A) polymorphism on efficacy of oxaliplatin+fluorouracil chemotherapy and survival time of advanced gastric cancer patients. METHODS: Totally 52 cases of advanced gastric cancer were selected from Hainan Provincial People’s Hospital during Jan. 2013-Jan. 2015. They were given oxaliplatin+fluorouracil chemotherapy, for 3 courses (a treatment course lasted for 3 weeks). The genotypes of patients were detected by PCR-LDR. Disease control rate and progression free survival were compared among different genotypes. RESULTS: Among 52 cases of advanced gastric cancer, there were 28 cases of XRCC1 GG genotype (53.8%), 21 cases of GA genotype (40.4%), 3 cases of AA genotype (5.8%), frequencies of which were all in line with Hardy-Weinberg balance (P>0.05). Disease control rates of 52 cases were 76.9%, among which disease control rate (92.9%) of GG genotype was significantly higher than that of GA+AA genotype (58.3%), with statistical significance (P<0.05). The average progression free survival of 52 cases was (7.1+1.2) months, among which progression free survival of GG genotype [(8.6±0.8)months] was significantly longer than that of GG+GA genotype [(5.9±0.7)months], with statistical significance (P<0.05). CONCLUSIONS: XRCC1 polymorphism is correlated with efficacy of oxaliplatin+fluorouracil chemotherapy and progression free survival, and XRCC1 GG genotype is more sensitive to chemotherapy drugs. XRCC1 gene can be regarded as predictive indicator for therapeutic efficacy of chemotherapy and survival.
期刊: 2017年第28卷第14期
作者: 钟兰,符生苗,谢贤和,黄涛,高允锁,林瑜
AUTHORS: ZHONG Lan,FU Shengmiao,XIE Xianhe,HUANG Tao,GAO Yunsuo,LIN Yu
关键字: XRCC1;基因多态性;晚期胃癌;奥沙利铂;氟尿嘧啶;化疗疗效;无进展生存期
KEYWORDS: XRCC1; Gene polymorphism; Advanced gastric cancer; Oxaliplatin; Fluorouracil; Efficacy of chemotherapy; Progression free survival
阅读数: 221 次
本月下载数: 10 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!